ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales

ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
Clinical Pain Advisor

Four Subtypes of Polycystic Ovary Syndrome Identified

Highest risk for second-trimester pregnancy loss and dyslipidemia incidence was seen for hyperandrogenic PCOS.

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week ...

Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate ...
Le Lézard

GC Biopharma Supports New Insights into Education, Safety, and Patient Outcomes in Ig Therapy Care at the 2025 IgNS Annual Meeting

GC Biopharma USA, Inc., a leader in plasma-derived products, announced today its support of data analysis and publication of the 2025 Immunoglobulin National Society (IgNS) Patient 360 Longitudinal ...

Emergent BioSolutions: Solid Q3, Expecting Better Days To Come

Emergent BioSolutions is rated Buy after a Q3 earnings beat, CEO turnaround progress, and improved financial outlook. Read ...